ACUTA Lifescience - PowerPoint PPT Presentation

1 / 17
About This Presentation
Title:

ACUTA Lifescience

Description:

Currently sterilization of pets is a surgical process. Procedure requires care ... Dr. Irwin Liu, DVM. Dr. Stephanie Bowles, DVM (PETA) Prof. Nitin Nohria ... – PowerPoint PPT presentation

Number of Views:235
Avg rating:3.0/5.0
Slides: 18
Provided by: djja
Category:

less

Transcript and Presenter's Notes

Title: ACUTA Lifescience


1
(No Transcript)
2
The Acuta Technology
Application 1 Pet Sterilization System
3
The Pet Sterilization System
0h 00m
4
Where is the need?
  • Currently sterilization of pets is a surgical
    process.
  • Procedure requires care before and afterwards.
  • Current alternatives are either temporary or
    ineffective.
  • Current private market size for companion animal
    sterilization services 960 Million in the US
    alone

5
Our Competition
  • A number of companies are planning to release
    non-surgical sterilization therapies.
  • Neutersol - chemical sterilant for male dogs
  • Spayvac - vaccines for female cats and dogs
  • Oral Vaccines - vaccines for female cats and
    dogs
  • None of these competitors offer the health
    benefits associated with surgery

6
Our Competition
  • One competitor offers both the health benefits,
    and the ability to sterilise both female and male
    animals.
  • Gonex
  • our research has shown fundamental problems in
    their technology.
  • Our approach avoids their technological problems

7
The Acuta Technology
Application 2 Hydrogel-Assisted Human Drug
Delivery
8
Hydrogel-Assisted Drug Delivery
9
Competitive Landscape All Small Molecule
Delivery
SG Cowen estimates
10
Acuta Edge
  • Very Large Macromolecule or Cell Delivery
  • Macromolecules (recombinant proteins, antibodies,
    DNA))
  • Antisense Therapy
  • Cell therapy
  • Strong Science (published PNAS, Biophys J.)

11
Company Timeline
12
Pre-Incorporation Q3 2002 Q2 2003
  • Chemical POCs
  • Conducted at Harvard Labs w/ David Edwards
    support

13
Pre-Incorporation Q3 2002 Q2 2003
  • Animal POCs
  • Result of POCs Published Paper

14
Post-Incorporation Q3 2003 Future
  • Increase in valuation based on PRE-Inc. work
  • Ready for intensive financing to fund prod. dev.
  • Hire management team, more key scientists
  • Pass FDA trials for PSS (qualify for expedited
    review)
  • Develop patented PSS mfg. process
  • Market and sell PSS w/ corp. partner
  • Cultivate co-dev. deals for hydrogel tech.

15
How much and when?
Seed Stage
Start-up Stage
16
Seed Stage
  • Approximate Funding Sought 200,000
  • Funding necessary for
  • Personnel
  • Equipment/Supplies
  • Legal Fees
  • Misc.
  • Sources of Funding
  • Competition Money
  • Angels
  • Bootstrapping
  • University Research Grants

17
Thank Yous
David Edwards Dan Deever Paul Bottino Jeff
Hrkach Howard Stone Nicolas Tsapis Megan
Valentine David Weitz George Whitesides Angeline
Warner
Heather Gunter Willow Diluzio Andre Valente Dr.
Charlie Damitz, DVM Dr. Craig Smith, DVM Dr.
Deborah Beck-Ross, DVM Dr. Irwin Liu, DVM Dr.
Stephanie Bowles, DVM (PETA) Prof. Nitin Nohria
Write a Comment
User Comments (0)
About PowerShow.com